Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Malignancies or Acute Lymphoblastic Leukemia

Trial Status: active

This phase I/Ib trial studies the side effects and best dose of autologous CD22 CAR T cells and to see how well it works in treating patients with B cell malignancies or acute lymphoblastic leukemia that has come back (recurrent) or does not respond to treatment (refractory). Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. In this study, some of patients' immune cells (called T cells) will be collected during a procedure called ‘leukapheresis’, and genetically modify them to recognize the antigen (marker) CD22 on cancer cells. CD22 is commonly found on B cell cancers. The CAR is a genetically-engineered receptor made recognize a specific molecule, which in this study is the CD22 protein, and activate or ‘turn on’ immune cells. Doctors use a type of virus to introduce the CAR receptor into patients' T cells to make the CD22 CAR T cells, so they may find and kill those cancer cells in the body.